INVITES BIOCORE CO., LTD
Invites Biocore, founded 2001 and KONEX-listed 2015, is a CRO offering bioequivalence, clinical, biochip, and quality testing services.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureInvites Biocore was founded in 2001 and listed on the KONEX market in 2015 as a contract research organization (CRO). Its core services span bioequivalence testing, bioanalysis, and Phase 0-3 clinical trial consulting, alongside biochip products such as DNA chips, protein chips, and PCR kits and a bio-logistics distribution business. The company holds Bio-analytical CRO GLP certification for toxicokinetics, serves more than 150 domestic pharmaceutical and biotech clients, and has partnerships with multinational firms including Pfizer and IQVIA.
Products & technology
- Bioequivalence CRO / Bioanalytical CROOutsourced bioequivalence testing for generic drugs before market launch
- Clinical CROManagement, monitoring, data management and statistical analysis for early-phase clinical trials
- Drug item testingAnalysis of drug quality attributes including appearance, moisture, identification, content, purity, and stability
- Elemental impurity testingICP-MS analysis of heavy metals such as lead, arsenic, and cadmium
- Nitrosamine impurity testingAnalysis of nitrosamine impurity content in pharmaceuticals
- DNA chip / Protein chip / PCR kitBiochip products developed in-house and commercialized
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition